Bhamik 2002.

Methods	Design: Open RCT
Participants	Inclusion criteria: biopsy proven primary FSGS, therapy‐resistant to oral prednisolone. Country: India. Number: 25 patients. Age: 3 to 49 years.
Interventions	Treatment group CSA plus oral prednisolone 10‐40 mg/d for 6 months. Control group Methylprednisolone 250‐750 mg IV daily for 7 days followed by weekly administration for at least 12 weeks.
Outcomes	Number with CR, PR with stable SCr. ESKD within 3 years. Decline in CrCl.
Notes	Previous prednisolone dose 2 mg/kg/d for 8 weeks. ESKD: 1/13 in the treatment group and 4/12 in the control group.
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment?	Low risk	A ‐ Adequate